The DynamX Bioadaptor drug-eluting stent (DES) is a new class of treatment for coronary artery disease with the unique property of adapting to vessel physiology. It has the potential to allow the vessel to expand with restoration of vasomotion resulting in better clinical outcomes. There is limited data on the outcomes of DynamX Bioadaptor DES in the setting of primary percutaneous coronary intervention (PPCI). We evaluated the clinical efficacy and safety of DynamX Bioadaptor DES in PPCI and report on the 30-day clinical outcomes.  

Between January 2021 to October 2021, 20 patients ( 80% male, mean age 57.7 ± 11.2 years) were treated with DynamX Bioadaptor DES during PPCI.  The primary endpoint was major adverse cardiac events (MACE) ie a composite of all-cause mortality, reinfarction and and target lesion revascularization (TLR) within 30 days of follow-up. 

The majority of patients presented with anterior ST-elevation myocardial infarction(60%) with the left anterior descending artery being the most common target vessel for PPCI followed by right coronary artery (40%). The majority of patients had single vessel disease (60%) on coronary angiography with 15% of patients having underlying diabetes mellitus. Mean left      ventricular function was 41 + 7 % with none in cardiogenic shock. All PPCI was performed by transradial intervention and the use of intracoronary imaging was 75% ( mostly intravascular ultrasound). Thrombus aspiration was performed in 40% of patients and the use of glycoprotein 2b/3a inhibitors was 85%. An average of 1.15 + 0.49 stent were used per patient with mean stent diameter of 3.1 ± 0.4 mm and average length of 28.6 ± 7.2 mm.  At 30-day follow-up, there was no death. There was also no reported reinfarction, TLR and stent thrombosis.   

Our preliminary experience showed that the use of DynamX Bioadaptor DES was feasible in PPCI and there was no reported 30-day MACE.   Longer follow-up in a larger cohort of patients is needed to confirm its long term safety and efficacy.